Prolonged Prophylaxis With Valganciclovir Is Cost Effective in Reducing Posttransplant Cytomegalovirus Disease Within the United States | Zendy

Emily A. Blumberg | Zendy; Ingeborg A. Hauser | Zendy; Sanja Stanisic | Zendy; E Mueller | Zendy; Karina Berenson | Zendy; C. G. Gahlemann | Zendy; Atul Humar | Zendy; Alan G. Jardine | Zendy

Open Access

Prolonged Prophylaxis With Valganciclovir Is Cost Effective in Reducing Posttransplant Cytomegalovirus Disease Within the United States

Author(s) -

Emily A. Blumberg,

Ingeborg A. Hauser,

Sanja Stanisic,

E Mueller,

Karina Berenson,

C. G. Gahlemann,

Atul Humar,

Alan G. Jardine

Publication year - 2010

Publication title -

transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.45

H-Index - 204

eISSN - 1534-6080

pISSN - 0041-1337

DOI - 10.1097/tp.0b013e3181ff500d

Subject(s) - valganciclovir , medicine , cost effectiveness , regimen , incidence (geometry) , cytomegalovirus , quality adjusted life year , cohort , intensive care medicine , ganciclovir , pediatrics , human cytomegalovirus , immunology , viral disease , herpesviridae , human immunodeficiency virus (hiv) , virus , risk analysis (engineering) , physics , optics

Cytomegalovirus (CMV) disease in transplant patients is known to have a substantial clinical and economic burden, and its prevention is expected to have long-term benefits. Evidence from the Improved Protection Against CMV in Transplant trial proved that prolonged prophylaxis of 200 days with valganciclovir compared with 100 days significantly reduces the incidence of CMV in high-risk kidney transplant seropositive donors/seronegative recipients. The aim of this study was to develop a cost-effectiveness model to evaluate prolonged prophylaxis of 200 days with valganciclovir and its long-term economic impact.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research